Answers are grounded in this paper and cite their sources.
Reveals that microtubule-stabilizing drugs reduce convulsions in C. elegans, indicating potential treatment options for neurodevelopmental seizure disorders.
Recessive, loss of function, genomic variants in CAMSAP1 and 2 (calmodulin-regulated spectrin-associated proteins 1 and 2) cause a neurodevelopmental seizure disorder in humans that currently lacks specific treatments. CAMSAP proteins stabilize dynamics of the minus-ends of microtubules and regulate regenerative signaling cascades. We explored microtubule-stabilizing drugs as potential therapeutic interventions using a convulsion assay in the model organism Caenorhabditis elegans . We found that animals with genetically disrupted ptrn-1 (the C. elegans homolog of CAMSAP1 ) exhibited elevated convulsion frequency relative to wild type, and that Epothilone B and Valproic Acid reduced convulsions. We also found that Paclitaxel increased convulsions, and Davunetide produced variable outcomes. These results suggest that pharmacologic microtubule stabilization is a promising strategy for diseases caused by genetic disruption to CAMSAP function. • Genetic disruption of CAMSAP homolog increases convulsion frequency in C. elegans . • Pharmacologic stabilization of microtubules reduces convulsions in C. elegans model • Epothiolone B and Davunetide reduce convulsions for CAMSAP ( ptrn-1 ) worms • Development of C. elegans model for CAMSAP seizure disorder drug screening
No takes yet. Share an insight, caveat, or question.
Schaak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: